

**Amendments to the Claims**

**This listing of claims will replace all prior versions and listings of claims.**

1-112. (Canceled)

113. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein encoded by the cDNA contained in ATCC Deposit Nos. 97149 from a host cell; and
- (b) recovering said protein.

114. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a natural source.

115. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

116. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a mammalian cell.

117. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a bacterial cell.

118. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a baculovirus cell.

119. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered from a yeast cell.

120. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered by chromatography.

121. (Previously Presented) The purified protein of claim 113, wherein the protein is recovered by an antibody.

122 (Previously Presented) The purified protein of claim 113, wherein the protein is a homodimer.

123. (Previously Presented) The purified protein of claim 113, wherein the protein is fused to a heterologous polypeptide.

124. (Previously Presented) A composition comprising the purified protein of claim 113 and a pharmaceutically acceptable carrier.

125. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has a wound, tissue, or bone damage.

126. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has ischemia.

127. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has had a myocardial infarction.

128. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

129. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has a wound, tissue, or bone damage.

130. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has ischemia.

131. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has had a myocardial infarction.

132. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 113, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

133-144. (Canceled)

145. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein comprising amino acids 71 to 396 of SEQ ID NO:2 from a host cell; and
- (b) recovering said protein.

146. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a natural source.

147. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

148. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a mammalian cell.

149. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a bacterial cell.

150. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a baculovirus cell.

151. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered from a yeast cell.

152. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered by chromatography.

153. (Previously Presented) The purified protein of claim 145, wherein the protein is recovered by an antibody.

154. (Previously Presented) The purified protein of claim 145, wherein the protein is a homodimer.

155. (Previously Presented) The purified protein of claim 145, wherein the protein is fused to a heterologous polypeptide.

156. (Previously Presented) A composition comprising the purified protein of claim 145 and a pharmaceutically acceptable carrier.

157. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has a wound, tissue, or bone damage.

158. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has ischemia.

159. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has had a myocardial infarction.

160. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

161. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has a wound, tissue, or bone damage.

162. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has ischemia.

163. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has had a myocardial infarction.

164. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 145, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

165. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein comprising amino acids 24 to 396 of SEQ ID NO:2 from a host cell; and
- (b) recovering said protein.

166. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a natural source.

167. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

168. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a mammalian cell.

169. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a bacterial cell.

170. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a baculovirus cell.

171. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered from a yeast cell.

172. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered by chromatography.

173. (Previously Presented) The purified protein of claim 165, wherein the protein is recovered by an antibody.

174. (Previously Presented) The purified protein of claim 165, wherein the protein is a homodimer.

175. (Previously Presented) The purified protein of claim 165, wherein the protein is fused to a heterologous polypeptide.

176. (Previously Presented) A composition comprising the purified protein of claim 165 and a pharmaceutically acceptable carrier.

177. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has a wound, tissue, or bone damage.

178. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has ischemia.

179. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has had a myocardial infarction.

180. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

181. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has a wound, tissue, or bone damage.

182. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has ischemia.

183. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has had a myocardial infarction.

184. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 165, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

185. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein comprising amino acids 1 to 396 of SEQ ID NO:2 from a host cell; and

(b) recovering said protein.

186. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a natural source.

187. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

188. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a mammalian cell.

189. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a bacterial cell.

190. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a baculovirus cell.

191. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered from a yeast cell.

192. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered by chromatography.

193. (Previously Presented) The purified protein of claim 185, wherein the protein is recovered by an antibody.

194. (Previously Presented) The purified protein of claim 185, wherein the protein is a homodimer.

195. (Previously Presented) The purified protein of claim 185, wherein the protein is fused to a heterologous polypeptide.

196. (Previously Presented) A composition comprising the purified protein of claim 185 and a pharmaceutically acceptable carrier.

197. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has a wound, tissue, or bone damage.

198. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has ischemia.

199. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has had a myocardial infarction.

200. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

201. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has a wound, tissue, or bone damage.

202. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has ischemia.

203. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has had a myocardial infarction.

204. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 185, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

205. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein comprising amino acids -23 to 396 of SEQ ID NO:2 from a host cell; and
- (b) recovering said protein.

206. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a natural source.

207. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

208. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a mammalian cell.

209. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a bacterial cell.

210. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a baculovirus cell.

211. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered from a yeast cell.

212. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered by chromatography.

213. (Previously Presented) The purified protein of claim 205, wherein the protein is recovered by an antibody.

214. (Previously Presented) The purified protein of claim 205, wherein the protein is a homodimer.

215. (Previously Presented) The purified protein of claim 205, wherein the protein is fused to a heterologous polypeptide.

216. (Previously Presented) A composition comprising the purified protein of claim 205 and a pharmaceutically acceptable carrier.

217. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has a wound, tissue, or bone damage.

218. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has ischemia.

219. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has had a myocardial infarction.

220. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

221. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has a wound, tissue, or bone damage.

222. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has ischemia.

223. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has had a myocardial infarction.

224. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 205, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

225. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of SEQ ID NO:2 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and promotes angiogenesis; and
- (b) recovering said protein fragment.

226. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a natural source.

227. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

228. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a mammalian cell.

229. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a bacterial cell.

230. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a baculovirus cell.

231. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered from a yeast cell.

232. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered by chromatography.

233. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is recovered by an antibody.

234. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is a homodimer.

235. (Previously Presented) The purified protein fragment of claim 225, wherein the protein fragment is fused to a heterologous polypeptide.

236. (Previously Presented) A composition comprising the purified protein fragment of claim 225 and a pharmaceutically acceptable carrier.

237. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has a wound, tissue, or bone damage.

238. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has ischemia.

239. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has had a myocardial infarction.

240. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

241. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has a wound, tissue, or bone damage.

242. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has ischemia.

243. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has had a myocardial infarction.

244. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 225, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

245. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of the protein encoded by the cDNA contained in ATCC Deposit No. 97149 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and promotes angiogenesis; and
- (b) recovering said protein fragment.

246. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a natural source.

247. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

248. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a mammalian cell.

249. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a bacterial cell.

250. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a baculovirus cell.

251. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered from a yeast cell.

252. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered by chromatography.

253. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is recovered by an antibody.

254. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is a homodimer.

255. (Previously Presented) The purified protein fragment of claim 245, wherein the protein fragment is fused to a heterologous polypeptide.

256. (Previously Presented) A composition comprising the purified protein fragment of claim 245 and a pharmaceutically acceptable carrier.

257. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has a wound, tissue, or bone damage.

258. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has ischemia.

259. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has had a myocardial infarction.

260. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

261. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has a wound, tissue, or bone damage.

262. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has ischemia.

263. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has had a myocardial infarction.

264. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 245, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

265. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of SEQ ID NO:2 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and proliferates endothelial cells; and
- (b) recovering said protein fragment.

266. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a natural source.

267. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

268. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a mammalian cell.

269. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a bacterial cell.

270. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a baculovirus cell.

271. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered from a yeast cell.

272. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered by chromatography.

273. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is recovered by an antibody.

274. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is a homodimer.

275. (Previously Presented) The purified protein fragment of claim 265, wherein the protein fragment is fused to a heterologous polypeptide.

276. (Previously Presented) A composition comprising the purified protein fragment of claim 265 and a pharmaceutically acceptable carrier.

277. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has a wound, tissue, or bone damage.

278. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has ischemia.

279. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has had a myocardial infarction.

280. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

281. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has a wound, tissue, or bone damage.

282. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has ischemia.

283. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has had a myocardial infarction.

284. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 265, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

285. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of the protein encoded by the cDNA contained in ATCC Deposit No. 97149 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and proliferates endothelial cells; and
- (b) recovering said protein fragment.

286. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a natural source.

287. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

288. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a mammalian cell.

289. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a bacterial cell.

290. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a baculovirus cell.

291. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered from a yeast cell.

292. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered by chromatography.

293. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is recovered by an antibody.

294. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is a homodimer.

295. (Previously Presented) The purified protein fragment of claim 285, wherein the protein fragment is fused to a heterologous polypeptide.

296. (Previously Presented) A composition comprising the purified protein fragment of claim 285 and a pharmaceutically acceptable carrier.

297. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has a wound, tissue, or bone damage.

298. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has ischemia.

299. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has had a myocardial infarction.

300. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

301. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has a wound, tissue, or bone damage.

302. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has ischemia.

303. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has had a myocardial infarction.

304. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 285, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

305-386. (Canceled)

387. (Previously Presented) A purified protein produced by the method comprising:

- (a) expressing a protein encoded by the cDNA contained in ATCC Deposit Nos. 75698 from a host cell; and
- (b) recovering said protein.

388. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a natural source.

389. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

390. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a mammalian cell.

391. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a bacterial cell.

392. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a baculovirus cell.

393. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered from a yeast cell.

394. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered by chromatography.

395. (Previously Presented) The purified protein of claim 387, wherein the protein is recovered by an antibody.

396. (Previously Presented) The purified protein of claim 387, wherein the protein is a homodimer.

397. (Previously Presented) The purified protein of claim 387, wherein the protein is fused to a heterologous polypeptide.

398. (Previously Presented) A composition comprising the purified protein of claim 387 and a pharmaceutically acceptable carrier.

399. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has a wound, tissue, or bone damage.

400. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has ischemia.

401. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has had a myocardial infarction.

402. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

403. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has a wound, tissue, or bone damage.

404. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has ischemia.

405. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has had a myocardial infarction.

406. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

407. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of the protein encoded by the cDNA contained in ATCC Deposit No. 75698 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and promotes angiogenesis; and
- (b) recovering said protein fragment.

408. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a natural source.

409. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

410. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a mammalian cell.

411. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a bacterial cell.

412. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a baculovirus cell.

413. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a yeast cell.

414. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered by chromatography.

415. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is recovered by an antibody.

416. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is a homodimer.

417. (Previously Presented) The purified protein fragment of claim 407, wherein the protein fragment is fused to a heterologous polypeptide.

418. (Previously Presented) A composition comprising the purified protein fragment of claim 407 and a pharmaceutically acceptable carrier.

419. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has a wound, tissue, or bone damage.

420. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has ischemia.

421. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has had a myocardial infarction.

422. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim

407, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

423. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has a wound, tissue, or bone damage.

424. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has ischemia.

425. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has had a myocardial infarction.

426. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

427. (Previously Presented) A purified protein fragment produced by the method comprising:

- (a) expressing a protein fragment of the protein encoded by the cDNA contained in ATCC Deposit No. 75698 from a host cell, wherein said protein fragment comprises amino acids 108-188 of SEQ ID NO:2 and proliferates endothelial cells; and
- (b) recovering said protein fragment.

428. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a natural source.

429. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

430. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a mammalian cell.

431. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a bacterial cell.

432. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a baculovirus cell.

433. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a yeast cell.

434. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered by chromatography.

435. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is recovered by an antibody.

436. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is a homodimer.

437. (Previously Presented) The purified protein fragment of claim 427, wherein the protein fragment is fused to a heterologous polypeptide.

438. (Previously Presented) A composition comprising the purified protein fragment of claim 427 and a pharmaceutically acceptable carrier.

439. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has a wound, tissue, or bone damage.

440. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has ischemia.

441. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has had a myocardial infarction.

442. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

443. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has a wound, tissue, or bone damage.

444. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has ischemia.

445. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has had a myocardial infarction.

446. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427,

wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.